TY - T1的疗效和安全性的pramipexole不宁腿综合症JF -神经学乔-神经病学SP - 1034 LP - 1039——10.1212/01. wnl首页.0000231513.23919。a1六世- 67 - 6非盟- j . w .温克曼主持盟- k·d·Sethi AU - c . a . Kushida盟p . m . Becker盟- j·凯斯特盟- j·j·Cappola AU - j·里斯Y1 - 2006/09/26 UR - //www.ez-admanager.com/content/67/6/1034.ab首页stract N2 -目的:评估的有效性和安全性pramipexole中度到重度的不宁腿综合症患者(RLS)方法:作者进行了12周,双盲、随机、安慰剂对照试验的固定剂量的pramipexole(0.25, 0.50,和0.75毫克/天)。患者(N = 344)被up-titrated随机剂量超过3周。主要疗效端点是病人的症状严重程度在国际RLS研究小组评定量表(irl)和临床评分的改善临床全球Impressions-Improvement (CGI-I)规模。次要疗效端点包括视觉模拟评分的睡眠和生活质量(QOL)结果:由主要措施,pramipexole优于安慰剂。irl,调整意味着(SE)改变从基线到第12周−9.3(1.0)安慰剂,−12.8(1.0)0.25毫克/天,−13.8(1.0)0.50毫克/天,和−14.0(1.0)为0.75毫克/天(所有p & lt;0.01)。同样,pramipexole CGI-I评级的患者的比例增加“改善”或“大大增加”的最后审判(安慰剂51.2%和74.7%、67.9%、72.9%,pramipexole;所有p & lt;0.05)。 Pramipexole significantly improved ratings of symptom severity, day and night, and also ratings of sleep satisfaction and QOL. Pramipexole was well tolerated: The most frequent adverse events with higher occurrence in the pramipexole group were nausea (19.0% vs 4.7%) and somnolence (10.1% vs 4.7%) Conclusion: As rated by patients and by clinicians, pramipexole was efficacious and safe in reducing the symptoms of restless legs syndrome. ER -